Brief: 3D Medicines Posts FY Revenue RMB634.9 Million
28/03/2024 06:08
March 28 (Reuters) - 3D Medicines Inc 1244.HK :
* FY REVENUE RMB634.9 MILLION VERSUS RMB567.4 MILLION
* FY ADJUSTED TOTAL COMPREHENSIVE LOSS RMB263.6 MILLION
VERSUS
LOSS RMB253.2 MILLION
Further company coverage: 1244.HK
((Reuters.Briefs@thomsonreuters.com;))
Recent news on 3D Medicines
See all newsBrief: 3D Medicines Inc Says Envafolimab Supplemental Application Accepted By NMPA
Brief: 3D Medicines Inc Says Zhang Jing Resigns As CFO
Brief: 3D Medicines Says New Drug Application For First-Line Treatment Of Biliary Tract Cancer Of Envafolimab Accepted
Brief: 3D Medicines Says Envafoimab Granted Orphan Drug Designation
Brief: 3D Medicines Inc Enters Strategic Agreement With Catug Biotechnology